Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
about
Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticePharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.
P2860
Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Efficacy and safety of switchi ...... ver 144 weeks: a cohort study.
@en
type
label
Efficacy and safety of switchi ...... ver 144 weeks: a cohort study.
@en
prefLabel
Efficacy and safety of switchi ...... ver 144 weeks: a cohort study.
@en
P2093
P2860
P1476
Efficacy and safety of switchi ...... ver 144 weeks: a cohort study.
@en
P2093
Charlotte Sueur
Christine Cheneau
Christine Koeppel
Claudine Bernard-Henry
Erik De Mautort
Marialuisa Partisani
Marie-Laure Batard
Michele Priester
Patrice Muret
P2860
P304
P356
10.3109/00365548.2014.947318
P577
2014-09-17T00:00:00Z